Search results
Results from the WOW.Com Content Network
Extracts from Camptotheca (the "happy tree" or "cancer tree") were used to develop the chemotherapeutic drug Topotecan. Plant sources of anti-cancer agents are plants, the derivatives of which have been shown to be usable for the treatment or prevention of cancer in humans. [1] [2]
Thymoquinone is a phytochemical compound found in the plant Nigella sativa. It is also found in select cultivated Monarda fistulosa plants which can be steam distilled to produce an essential oil. It has been classified as a pan-assay interference compound , which binds indiscriminately to many proteins. [ 1 ]
They say "there is currently no evidence that aloe products can help to prevent or treat cancer in humans". [55] Andrographis paniculata – a herb used in Ayurvedic medicine, and promoted as a dietary supplement for cancer prevention and cure. The Memorial Sloan Kettering Cancer Center has stated that there is no evidence that it helps prevent ...
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source , are explained in Nomenclature of monoclonal antibodies .
It is one of the most famous non-proteinogenic amino acid and was characterized in 1956 by Henry W Dion et al., [3] who suggested a possible use in cancer therapy. This antitumoral efficacy was confirmed in different animal models. [ 4 ]
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [2] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [3] and PARP inhibitors such as olaparib. [4]
Cancer immunoprevention is the prevention of cancer onset with immunological means such as vaccines, immunostimulators or antibodies. [1] [2] Cancer immunoprevention is conceptually different from cancer immunotherapy, which aims at stimulating immunity in patients only after tumor onset, however the same immunological means can be used both in immunoprevention and in immunotherapy.
The drug (originally known as MT103) was developed by a German-American company Micromet, Inc. in cooperation with Lonza; In 2012, Micromet was purchased by Amgen, which furthered the drug's clinical trials. In July 2014, the FDA granted breakthrough therapy status to blinatumomab for the treatment of acute lymphoblastic leukemia (ALL). [12]